NUS-Kanagawa Symposium 2023
National University of Singapore
NUS Centre for Life Science (CeLS) Auditorium, Level 1
28 Medical Drive, Singapore 117456
4-5 September 2023 | Singapore
NUS-Kanagawa Symposium 2023 welcomes you!
The NUS-Kanagawa Symposium 2023: Advances in Cancer Research, held on 4th – 5th September, is a high-profile two-day conference with a lineup of renowned speakers. The symposium will present cutting edge research focusing on onco-immunology, RNA biology, genomics and ageing.
Jointly organized by the Cancer Science Institute of Singapore (CSI Singapore) and the NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine in collaboration with Kanagawa Cancer Center Research Institute, Yokohama City University School of Medicine and the Kanagawa Prefectural Government, this meeting brings together leading researchers and students from NUS, the Kanagawa Cancer Center and the Yokohama City University, as well as government and industry representatives, with the aim of fostering greater collaboration in cancer-related fields across Singapore and Japan.
NUS-Kanagawa Symposium 2023 Speakers
Guest of Honour
John Eu-Li WONG
Professor John Eu-Li WONG
Isabel Chan Professor in Medical Sciences
Executive Director, Centre for Population Health
NATIONAL UNIVERSITY OF SINGAPORE
Senior Advisor
NATIONAL UNIVERSITY HEALTH SYSTEM
Dr John Eu-Li Wong is the Isabel Chan Professor in Medical Sciences; Executive Director, Centre for Population Health, National University of Singapore (NUS); and Senior Advisor, National University Health System (NUHS) Singapore.
A medical oncologist-haematologist, Professor Wong obtained his medical degree from NUS and did his post graduate training in both Singapore and the United States (US), at the New York Hospital-Cornell Medical Center, where he was the Chief Resident in Medicine, and Memorial Sloan-Kettering Cancer Center.
He was the founding director, National University Cancer Institute, Singapore; jointly founded the Cancer Therapeutics Research Group, a multinational consortium of nine academic institutions; served on the International Education Council for Molecular Targeted Therapy for Cancer, the American Society of Clinical Oncology International Affairs Committee, and the International Oncology Foundation Advisory Board.
He is Co-Chair of the US National Academy of Medicine Commission for a Global Roadmap for Healthy Longevity; Commissioner, Lancet Commission on 21st Century Global Health Threats; Member, Advisory Committee, Harvard University’s T.H. Chan School of Public Health, The Culinary Institute of America, and the Association Montessori Internationale on Healthy Aging, Diet and Lifestyle.
He sits on the Editorial Board, Journal of the American Medical Association, received an honorary Degree of Doctor Philosophiae Honoris Causa from the Hebrew University of Jerusalem, is an international member of the US National Academy of Medicine, and an elected member of Academia Europaea. He is a Fellow of the Academy of Medicine Singapore, the Royal College of Physicians in Edinburgh and London, and the American College of Physicians.
National University of Singapore (NUS) Speakers
Polly Leilei CHEN
Polly Leilei CHEN
Associate Professor and Principal Investigator, Cancer Science Institute of Singapore, NUS
Dr Polly Leilei Chen received her Bachelor of Medicine and completed her medical training in China and then pursued her PhD (2010) at the University of Hong Kong. In 2014, Dr Chen joined National University of Singapore (NUS) as a Principal Investigator at Cancer Science Institute of Singapore and Assistant Professor in the Department of Anatomy. She was promoted to Associate Professor in 2021. Dr Chen is an EMBO Young Investigator and Asian RNA Research Ambassador. She currently places her research focus on functional and mechanistic investigation of RNA changes (particularly RNA editing and splicing) leading to cancer initiation and development; and the development of novel cancer therapies targeting these cancer-associated RNA changes.
Wee Joo CHNG
Wee Joo CHNG
Yong Loo Lin Professor in Medical Oncology & Vice-Dean (Research), Yong Loo Lin School of Medicine, NUS
Director & Senior Consultant, National University Cancer Institute, Singapore, NUHS
Group Director of Research, National University Health System
Senior Principal Investigator, Cancer Science Institute of Singapore, NUS
Professor Wee Joo Chng is a Yong Loo Lin Professor in Medical Oncology and Vice Dean of Research at the Yong Loo Lin School of Medicine, National University of Singapore, where he is also a Senior Principal Investigator at the Cancer Science Institute of Singapore. He is concurrently the Director of the National University Cancer Institute, Singapore and the Group Director of Research, at the National University Health System.
Professor Chng sits on many international professional committees, such as the International Myeloma Working Group and the Asian Myeloma Network. He is involved in a number of Grant Review Committees, Conference Organising Committees, Advisory Boards and Steering Committees of Global Clinical Trials. He has authored more than 300 publications in many reputed journals and delivered talks at national and international conferences, and also actively participates in clinical trials. He has won multiple awards for his outstanding research including the NUHS Research Excellence Award, the International Myeloma Foundation’s Brian GM Durie Outstanding Achievement Award, the National Medical Excellence Outstanding Clinician Scientist Award, the National Medical Research Council Senior Translational Research (STaR) Award, the National University of Singapore Young Researcher Award, and the Celgene Future Leaders in Haematology Award.
Dennis KAPPEI
Dennis KAPPEI
Principal Investigator, Cancer Science Institute of Singapore, NUS
Assistant Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, NUS
Dennis Kappei is a Principal Investigator and the Head of the Quantitative Proteomics Core at the Cancer Science Institute of Singapore (CSI) and an Assistant Professor in the Department of Biochemistry in the Yong Loo Lin School of Medicine at the National University of Singapore. Dr Kappei obtained his MS degree from Ecole Normale Supérieure and University Paris VI and pursued his graduate studies at the Max Planck Institute of Molecular Cell Biology and Genetics under the roof of the Dresden International Graduate School for Biomedicine and Bioengineering.
Anthony KHONG
Anthony KHONG
Principal Investigator, Cancer Science Institute of Singapore, NUS
Assistant Professor, Department of Physiology, Yong Loo Lin School of Medicine, NUS
Dr. Khong is an assistant professor at the Cancer Science Institute of Singapore and the Department of Physiology at the National University of Singapore. Dr. Khong obtained his Bachelor of Science at the University of British Columbia in 2008. He then obtained his Doctorate of Philosophy in Biochemistry and Molecular Biology at the University of British Columbia in 2015. Dr. Khong completed his postdoctoral training at the University of Colorado Boulder under the supervision of Professor Roy Parker in April 2023. In his academic career, he published 18 papers, including seven first-author research articles, and was awarded a Banting Postdoctoral Fellowship. Dr. Khong’s main research areas are RNA biology and stress granules, a model biomolecular condensate that forms during cellular stress. Dr. Khong’s recent research has provided fundamental insights into why cells build stress granules. Specifically, his studies have led to the idea that stress granules form as a biophysical consequence of extensive mRNA-mRNA aggregation during translational shutoff. Moreover, his recent study indicates stress granules promote chemoresistance by promoting cell-cycle exit. Dr. Khong plans to continue dissecting how stress granules and RNA granules modulate gene expression and participate in cancer biology at the National University of Singapore.
Derrick ONG
Derrick ONG
Assistant Professor, Department of Physiology, National University of Singapore
NUS Centre for Cancer Research
Derrick is the President’s Assistant Professor at the Department of Physiology, National University of Singapore (NUS). He obtained his PhD (Chemical Biology) at The Scripps Research Institute (CA) where he trained under Dr Jeffery Kelly, a pioneer in proteostasis. For his postdoctoral work, Derrick was mentored by Dr Ronald DePinho, a world expert in aging and cancer, first at Dana Farber Cancer Institute/ Harvard Medical School, and then University of Texas MD Anderson Cancer Center. His major research interest lies in the area of glioblastoma and cancer epigenetics.
ONG Sin Tiong
ONG Sin Tiong
Associate Professor, Duke-NUS Medical School
Dr. Ong is a practising haematologist/oncologist who studies mechanisms of cancer drug resistance at the Cancer & Stem Cell Biology Signature Research Programme in Duke-NUS Medical School in Singapore. Dr. Ong received his undergraduate degree in Medical Sciences from Cambridge University. He performed his internal medicine training at Addenbrooke’s Hospital Cambridge and National University Hospital Singapore, and his subspecialty training at the University of Chicago. In 2007, Dr. Ong was recruited back to Singapore to join Duke-NUS, where he expanded his research portfolio to include genomics-based studies, drug development, as well as solid tumours, such as lung and brain cancers. His Singapore-based discoveries include the first East Asian gene variant to confer general resistance to cancer targeted therapies, novel drug targets in the cancer cell’s translational machinery, and bioinformatics-based approaches to dismantling cancer cell states. He has partnered with A*STAR entities in Singapore to also develop novel MNK kinases (ETC-206) which are currently in clinical trials. His work has been published in Nature Medicine, Cancer Research, Blood, Leukemia, and the Proceedings of the National Academy of Sciences. He has received past and current funding from the US NIH, National Medical Research Council Singapore, and the Lymphoma and Leukemia Society.
Patrick TAN
Patrick TAN
Professor, Senior Vice Dean of Research, Duke-NUS Medical School
Chief Scientific Officer, Genome Institute of Singapore
Senior Principal Investigator, Cancer Science Institute of Singapore
Prof. Patrick Tan is Senior Vice Dean of Research at Duke-NUS Medical School and Chief Scientific Officer at the Genome Institute of Singapore. He is a Senior Principal Investigator at the Cancer Science Institute of Singapore, Executive Director of PRECISE (Precision Health Research Singapore) coordinating Singapore’s National Precision Medicine program, and Professor (adjunct) at Duke University, USA. He received his B.A. (summa cum laude) from Harvard University and MD PhD degree from Stanford University, where he received the Charles Yanofsky prize for Most Outstanding Graduate Thesis in Physics, Biology or Chemistry. Other awards include the President’s Scholarship, Loke Cheng Kim scholarship, Young Scientist Award (A-STAR), Singapore Youth Award (twice), Chen New Investigator Award (Human Genome Organization), President’s Science Award, Japanese Cancer Association International Award and Public Administration Medal (Silver). In 2018, he received the American Association for Cancer Research (AACR) Team Science Award as Team Leader. He is an elected member of the American Society for Clinical Investigation (ASCI), the Bioethics Advisory Committee (BAC), a Board Member of the International Gastric Cancer Association, Board of Reviewing Editors for Science, and on advisory committees for Venture Corporation, Qatar Precision Health Institute, and Riyadh Biotech City (Saudi Arabia).
Yokohama City University (YCU) Speakers
Hisashi HASUMI
Hisashi HASUMI
Associate Professor, Department of Urology, Yokohama City University
Dr. Hasumi is a urologic surgeon who has been focusing on renal tumorigenesis under dysregulation of kidney cancer-associated genes. His aim is to develop the foundation of precision medicine for kidney cancer.
Hideaki NAKAJIMA
Hideaki NAKAJIMA
Professor and Chairman, Department of Stem Cell and Immune Regulation,
Yokohama City University Graduate School of Medicine
Dr. Nakajima is an adult hematologist and a physician scientist, currently appointed as Professor and Chairman of Department of Hematology and Clinical Immunology in Yokohama City University School of Medicine. He is an executive board member of Japanese Society of Hematology (JSH) and the Japanese Society of Internal Medicine, as well as a member of International Members Committee and the Awards Committee of American Society of Hematology (ASH). He started his research career with studies on differentiation inducing therapy of acute myeloid leukemia (AML) at Keio University School of Medicine, which led to his pioneering works on signaling and transcriptional regulation of hematopoiesis at St. Jude Children’s Research Hospital and the University of Tokyo. His current research focuses on the epigenetic and transcriptional regulation of myeloid malignancies, clonal hematopoiesis, and hematopoietic stem cells.
Tomohiko TAMURA
Tomohiko TAMURA
Professor, Department of Immunology,
Yokohama City University Graduate School of Medicine
Dr. Tamura obtained M.D. and Ph.D. at Yokohama City University. As a clinician, he specialized in hematopoietic stem cell transplantation. As a basic scientist, he has been studying the role of transcription factors in myeloid cell development and function at NICHD, NIH, the University of Tokyo, and Yokohama City University, particularly from the viewpoint of chromatin. He loves listening to classical and jazz music using sophisticated audio systems.
Kensuke TATEISHI
Kensuke TATEISHI
Associate Professor and Principal Investigator, Department of Neurosurgery and Medical Life Science, Yokohama City University
Dr. Tateishi is currently working as a neurosurgeon and principal investigator at Yokohama City University (YCU) and YCU hospital. His team’s research goal is to elucidate tumor progressive mechanism and to establish novel therapeutic strategy for malignant brain tumors, including glioma and primary central nervous system lymphoma. To complete this, they have established the large scale of patient-derived xenograft models. Using these models, they are conducting translational research with collaborators.
Jordan RAMILOWSKI
Jordan RAMILOWSKI
Associate Professor, Yokohama City University Bioinformatics Laboratory
Jordan Ramilowski graduated with a Ph.D. in Physical Chemistry from Utah State University (US). In 2011, Dr. Ramilowski moved to RIKEN Yokohama Institute (Japan) where he worked as a Bioinformatics Researcher largely focusing on understanding roles of long non-coding RNAs in gene regulation. Since 2020, Dr. Ramilowski has been appointed a Bioinformatics Associated Professor at the Advanced Medical Research Center at Yokohama City University, where he is primarily investigating regulatory roles of long non-coding RNAs (lnc-RNAs) in immune cell differentiation and pathology.
Central Institute for Experimental Animals (CIEA) Speakers
Teja CELHAR
Teja CELHAR
Senior Research Scientist, Singapore Immunology Network, A*STAR
Central Institute for Experimental Animals (CIEA)
Dr. Teja Celhar received her MSci in Pharmacy and Ph.D. in Biomedicine from the University of Ljubljana, Slovenia. She joined the Singapore Immunology Network in 2010 as a research fellow in Dr. Anna-Marie Fairhurst’s Autoimmunity lab. During her postdoctoral training, she gained extensive knowledge of murine models of disease, particularly systemic lupus erythematosus. She joined the “Humanized NOG Mice for Immuno Therapy – HuNIT” platform in April 2019, where she is involved in the isolation and characterization of CD34+ hematopoietic stem/progenitor cells, generation of human immune system humanized mice and evaluation of novel models for Immuno-Oncology and Autoimmunity.
Makoto SUEMATSU
Makoto SUEMATSU
Director, Central Institute for Experimental Animals
Dr. Suematsu, Professor and Chair at Department of Biochemistry, Keio University, is a physician scientest who is interested in how gases such as NO, CO and H2S exert their biological actions. This concept shed light on mechanisms by which cancer utilizes the gas-responsive receptors to take advantage of energy maintenance for survival. His carrier as Dean of Keio University School of Medicine enabled to launch "Supercentenarian Medical Research Center" that contributed to global collaboration in aging sciences. In April 2015, he was appointed by the late prime minister Abe to be the founding president of Japan Agency for Medical Research and Development (AMED). He concluded MOC in January 2016 with NIH to accelerate global data sharing in the field of rare and undiagnosed diseases, etc.. From April 2023, he became Professor Emeritus, Keio University, and Director of Central Institute of Experimental Animals.
Takeshi TAKAHASHI
Takeshi TAKAHASHI
General Manager, Dept. of Basic Research for Laboratory Animals
Central Institute for Experimental Animals (CIEA)
2011- Head, Immunology Laboratory, Laboratory Animal Research Department, Central Institute for Experimental Animals (CIEA)
2006-2011 Assistant Prof., Dept. of Microbiology and Immunology, Tohoku University
2004-2006 Visiting Scientist, Deutsches Rheuma-Forschungszentrum Berlin
2003-2004 Visiting Scientist, Stanford University
2001-2003 Assistant Prof., Institute for frontier medical sciences, Kyoto University
1999-2001 Postdoc. fellow, Institute for frontier medical sciences, Kyoto University
1998-1999 Postdoctoral fellow, Tokyo metropolitan Institute for gerontology
1994-1998 Osaka University Graduate school of Medicine (Ph.D. 1998)
Kanagawa Cancer Center (KCC) Speakers
Shiro KOIZUME
Shiro KOIZUME
Chief Scientist, Kanagawa Cancer Center Research Institute
1997 Graduate School of Pharmaceutical Sciences Hokkaido University
2005-2010 Research Scientist, Kanagawa Cancer Center Research Institute, Japan
2010- Present Chief Scientist, Kanagawa Cancer Center Research Institute, Japan
Specialty and Present Interest: Gene regulatory mechanisms associated with cancer progression, Cancer-associated thromboembolism.
Hiroto NARIMATSU
Hiroto NARIMATSU
Director and Professor, Center for Innovation Policy, Kanagawa University of Human Services
Division Chief, Kanagawa Cancer Center Research Institute
Physician and researcher.
Through a cross-appointment system, Dr. Narimatsu is enrolled at both Kanagawa Cancer Center and Kanagawa University of Human Services, working toward a society where people can design their own health through innovation. He is also involved in the implementation of innovation in the community as the Chairman of CIKOP, Specified Nonprofit Corporation, based in Yamagata and Kanagawa Prefectures.
Tetsuro SASADA
Tetsuro SASADA
Director, Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center
Division Chief, Kanagawa Cancer Center Research Institute
Dr. Sasada received MD (1987) and PhD (1997) from Kyoto University, Kyoto, Japan. After his training in gastroenterological surgery and immunology, he worked as the Director of the Immune Assessment Core at the Cancer Vaccine Center in Dana-Farber Cancer Institute, Boston from 2006 to 2010. After then, from 2010 to 2014, he studied cancer peptide vaccines at Kurume University School of Medicine, Fukuoka, Japan. In 2014, he moved to Kanagawa Cancer Center, Yokohama, Japan, and has been involved in the preclinical and clinical development of novel cancer immunotherapies.
Shinya SATO
Shinya SATO
Section Chief, Kanagawa Cancer Center Research Institute
Dr. Sato graduated from Nagoya City University School of Medicine in 2003. After initial training at the Aichi Cancer Center, he worked as a pathologist in the Department of Experimental Pathology, performing diagnostic work and studying metastatic microenvironment in rats. In 2016, he joined Prof. Alissa Weaver in the Department of Cancer Biology at Vanderbilt University to study the relationship between extracellular vesicles and metastasis, and showed that cancer cell-derived extracellular vesicles are involved in angiogenesis in the cancer microenvironment. After returning to Japan in 2019, he joined the Kanagawa Cancer Center Research Institute, where he continues to study cancer-adipocyte interactions using cell, animal, and biobank materials.
Symposium Program
|
Monday 4th September 2023 |
||
|
Time |
Item | Duration |
| 1230 onwards | Registration (CeLS Foyer) |
- |
| (1300 – 1320) | Opening Address | |
| 1300 - 1303 |
Yugi Kuroiwa |
3 mins |
| 1303 – 1310 | Yohei Miyagi Director, Kanagawa Cancer Center Research Institute |
7 mins |
| 1310 – 1320 | Chng Wee Joo Vice President (Biomedical Sciences Research), Office of the Deputy President (Research and Technology), NUS Yong Loo Lin Professor in Medical Oncology & Vice Dean (Research), Yong Loo Lin School of Medicine, NUS Group Director of Research, National University Health System Senior Consultant, National University Cancer Institute, Singapore, NUHS Senior Principal Investigator, Cancer Science Institute of Singapore, NUS |
10 mins |
|
Theme: Leukemia Chairperson: Toshio Suda |
||
| 1320 – 1340 |
Chng Wee Joo MAF-Driven Metabolic Reprogramming Mediates H3K27 Hyperacetylation to Regulate Super Enhancer-Associated Genes |
20 mins |
| 1340 – 1400 |
Ong Sin Tiong What Can We Learn from Single Cell Studies in Chronic Myeloid Leukaemia? |
20 mins |
| 1400 – 1420 |
Hideaki Nakajima Deciphering the Mechanism of Chemoresistance in Poor-Risk AML |
20 mins |
|
Theme: Gastric Cancer & Tumour Niche Chairperson: Hideaki Nakajima |
||
| 1420 – 1440 |
Patrick Tan Genomic Landscapes of Gastric Pre-malignancy |
20 mins |
| 1440 – 1500 |
Shiro Koizume Malignant Phenotypes of Ovarian Cancer Induced Under Lipid Starvation and Hypoxia Condition |
20 mins |
| 1500 – 1530 | Introduction of Industry Representatives | 30 mins |
| 1530 – 1600 | Coffee Break | 30 mins |
|
Theme: Proteome and RNA Biology Chairperson: Patrick Tan |
||
| 1600 - 1620 |
Dennis Kappei Identification of Biomarkers and Therapeutic Targets in Gastric Cancer by Label-Free Quantitative Mass Spectrometry |
20 mins |
| 1620 - 1640 |
Jordan Ramilowski Coordinated Expression of Long Noncoding-RNA Regulates Lineage Commitment of Classical Dendritic Cells |
20 mins |
| 1640 - 1700 |
Polly Leilei Chen RNA “Mutations” in Cancer: Are They Silent? |
20 mins |
| 1700 – 1720 |
Anthony Khong Stress Granules Promote p21 Expression and Chemoresistance |
20 mins |
| 1720 | End of Session for 1st Day | |
|
Tuesday 5th September 2023 |
||
|
Time |
Item |
Duration |
|
Theme: Immunology Chairperson: Dennis Kappei |
||
| 0900 - 0920 | Tomohiko Tamura Professor, Department of Immunology, Yokohama City University Graduate School of Medicine Chromatin and the Transcription Factor IRF8 in the Regulation of Myeloid Cell Development |
20 mins |
| 0920 – 0940 |
Tetsuro Sasada Predictive Biomarkers of Immune Checkpoint Inhibitors for Development of Personalized Immunotherapy |
20 mins |
|
Theme: Biobanking & Mouse Models Chairperson: Yohei Miyagi |
||
| 0940 – 1000 |
Shinya Sato Analysis of Cancer Adipocyte Microenvironment Using High Quality and Diverse Data Modalities of Biobank in the Kanagawa Cancer Center |
20 mins |
| 1000 – 1010 |
Teja Celhar Transgenic Expression of Human Cytokines Impacts the Tumor Immune Microenvironment in Humanized NOG mice |
10 mins |
| 1010 - 1020 |
Takeshi Takahashi Induction of Anti-Tumor Immunology by Immune-Checkpoint Inhibitors in Humanized Mice |
10 mins |
| 1020 - 1040 | Coffee Break | 20 mins |
|
Theme: Renal & Brain Cancer Chairperson: Tomohiko Tamura |
||
| 1040 – 1100 |
Hisashi Hasumi Development of Foundation of the Precision Medicine for Kidney Cancer |
20 mins |
| 1100 - 1120 |
Derrick Ong Towards a Better Molecular Understanding of Glioblastoma Pathogenesis |
20 mins |
| 1120 - 1140 |
Kensuke Tateishi Translational Research Platform for Malignant Brain Tumors |
20 mins |
| 1140 - 1200 |
Makoto Suematsu Imaging Metabolomics Deciphers Cancer Metabolism to Translate into Medicine |
20 mins |
|
Theme: Aging Chairperson: Toshio Suda |
||
| 1200 - 1205 |
Yuichi Tei /Ung-il Chung Executive Board Member, Vice President and Dean, School of Health Innovation, Kanagawa University of Human Services, Kanagawa, Japan |
5 mins |
| 1205 – 1225 |
Hiroto Narimatsu Community-Based Intervention and Robot Suit HAL |
20 mins |
| Closing Address | ||
| 1225 – 1235 | John Eu-Li Wong Isabel Chan Professor in Medical Sciences Executive Director, Centre for Population Health, National University of Singapore Senior Advisor, National University Health System (NUHS) Singapore |
10 mins |
|
1235 |
End of Symposium - Lunch | |
Venue
National University of Singapore
NUS Centre for Life Science (CeLS) Auditorium, Level 1
28 Medical Drive, Singapore 117456
Symposium Registration
- Symposium dates: 4-5 September 2023
- Registration is now closed.
Sponsors
Organizing Committee
Toshio SUDA
Toshio SUDA
Senior Principal Investigator, Cancer Science Institute of Singapore
Toshio Suda, M.D, Ph.D is a Professor from Department of Medicine at Yong Loo Lin School of Medicine and a Senior Principal Investigator at Cancer Science Institute of Singapore, National University of Singapore. Dr Suda has studied hematopoietic stem cells (HSCs) and cancer HSC niches for over forty years. His past work encompasses the purification of HSCs, identification of cytokine signaling in hematopoiesis, and the characterization of HSC niches in bone marrow (BM). Although stem cells differentiate along with a cell autonomous intrinsic program, this process is influenced by the microenvironment of the stem cells niche. He identified the endosteal niche for HSC niche (Cell, 2004), and subsequently established the new field of oxidative stress and stem cell aging (Nature, 2004 and Nature Med, 2006). Dr. Suda has shown that niche cells regulate stem cells through direct adhesion and through the secretion of humoral niche factors such as cytokines, chemokines and extracellular matrix molecules. Together, these niche components and stem cells are thought to form a functioning unit to maintain tissue homeostasis. Dr Suda is also a recipient of the 2020 E. Donnall Thomas Lecture and Prize (American Society of Hematology (ASH) Honorific Award) in recognition for his outstanding contributions to the field of stem cell research.
Alan Prem KUMAR
Alan Prem KUMAR
Research Assistant Professor, Department of Pharmacology, Yong Loo Lin School of Medicine, NUS
I am an Assistant Professor at the Department of Pharmacology, NUS Medicine with Admin roles as the Deputy Director in the Office of Postdoctoral Affairs, Dean's Office, a portfolio to support the postdoc community at our school, which includes personal development, professional training, and facilitation of open communication. I am also the Academic Outreach Lead in the Office of Vice-Dean Research, Dean's Office with a portfolio to establish academic collaborations with external partners. In recent student supervision awards, I am a 2-time Recipient of the Yong Loo Lin School of Medicine, NUS Graduate Mentor of the Year Award 2017 & 2021 for excellence in graduate supervision, intellectual and professional development of my graduate students. My laboratory is focused on uncovering new cues that drive the spread of cancer and develop target-based precision therapies to prevent metastasis in several types of female reproductive cancers. My contribution to translational research gained me a 3-time Recipient of World’s Highly Cited Researchers™ 2020, 2021 & 2022 by Clarivate. The highly anticipated list of Highly Cited Researchers™ identifies researchers who demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers. I am also listed as Top 2% of Scientists Worldwide in a study from Stanford University and also listed in Research.com World’s Best Biology and Biochemistry Scientists 2023, awarded Biology and Biochemistry in Singapore Leader Award 2023. I sit on the Scientific Advisory Boards for GenoMed, Inc., USA (Oncology Markers); Sansad Mobile Swasthya Seva Healthcare Program, Parliament of India, India (Breast Cancer Awareness and Screening); The Sparks Foundation, Singapore (Education); and AUM Biosciences, Singapore (Oncology Drug Acquisitions).
Yohei MIYAGI
Yohei MIYAGI
Professor and Director, Cancer Molecular Pathology & Genetics Division, Kanagawa Cancer Center Research Institute
Yohei Miyagi is professor in Molecular Pathology and Genetics Division in the Kanagawa Cancer Center Research Institute, in Japan. Yohei Miyagi's research interests are in Molecular Biology, Biotechnology, Cell Biology, Bioinformatics, Cancer Research, Immunology, Developmental Biology, Evolutionary Biology. Yohei Miyagi's research had been published in a number of major international journals.
